News / Taiwan / economic_daily
Anchen Biotech Targets Q4 Data Readout for Rare Disease Drug, Eyes IPO
Health Technology · Biotechnology · economic_daily · 2026-10-06
6610
Anchen Biotech plans to release Phase 3 clinical trial results for its 'butterfly skin' disease drug AC-203 in Q4, with potential US approval and IPO to follow.
What Happened
Clinical Development Milestone: Anchen Biotech has announced that its global pivotal trial for AC-203, a treatment for epidermolysis bullosa, is on track for a data readout in the fourth quarter of this year. Successful results will pave the way for a US drug application and international licensing deals in the first half of next year.
Capital and IPO Plans: The company recently completed a capital increase of NT$450 million through the issuance of 18 million shares to support its R&D pipeline. Chairman Wu Yi-chun stated that once the commercial licensing for AC-203 is secured, the company intends to initiate its initial public offering (IPO) process.
Market Potential and Strategy: Targeting a rare disease with approximately 500,000 patients globally, AC-203 represents a significant market opportunity with estimated annual treatment costs between $100,000 and $300,000 per patient. The company is also exploring the potential monetization of a US Priority Review Voucher (PRV) to generate additional revenue streams.
Diversified Pipeline: Beyond AC-203, Anchen is advancing its AC-1101 candidate for alopecia areata, with Phase 2a trials scheduled to begin by year-end. Management emphasizes that leveraging existing networks with international medical teams will accelerate their development efforts in the dermatology space.